Metastatic melanoma patients treated with pembrolizumab who achieve a complete response can maintain those responses, even after discontinuation of therapy.
Among patients with relapsed or refractory multiple myeloma, adding carfilzomib to lenalidomide and dexamethasone improves overall survival compared with lenalidomide and dexamethasone alone.
PD-L1 expression was more common among patients with the GCB subtype of diffuse large B-cell lymphoma, and PD-L1 positivity predicted shorter survival.
Which genetic mutation confers shorter progression-free survival in myelofibrosis patients undergoing allogeneic stem cell transplantation? And what is the only potentially curative treatment for primary myelofibrosis? Test your knowledge in our latest quiz.
Treatment with carfilzomib for multiple myeloma was associated with increased incidence of cardiovascular adverse events, especially with higher doses.
A new study has shown several ways that the health-related quality of life in cancer patients older than 65 years could be improved.
BCR-ABL1 transcript levels at time points within the first year of therapy for CML can best predict the achievement of a deep molecular response.
A 14-year-old girl presents with a soft-tissue mass at the level of the cauda equina. Based on the image shown, what is your diagnosis?
The FDA has granted priority review to the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations after complete disease resection.
Continuous treatment with lenalidomide/dexamethasone significantly improved survival in patients with transplant-ineligible newly diagnosed multiple myeloma.
An individual risk–based approach could identify more people eligible for lung cancer screening, and thus prevent more early deaths, compared with USPSTF criteria.
Experience with the recently enacted California End of Life Option Act has shown that a high percentage of patients who requested aid-in-dying drugs in California have proceeded with ingesting the drugs. The majority of these requests were made by terminal cancer patients.
The FDA has expanded the label for cabozantinib (Cabometyx) to include first-line treatment of advanced renal cell carcinoma regardless of treatment status. Cabozantinib was initially approved in patients who had previously received anti-angiogenic therapy.
The combination of exosomal RNA and cell-free DNA improved the sensitivity of blood-based liquid biopsy for EGFR mutation detection in non–small-cell lung cancer compared with standard circulating tumor DNA.
Educational strategies including pamphlets and recommendations from family physicians and support from a specialist can improve bone care in men with prostate cancer undergoing androgen deprivation therapy.